This is a clip from our event with BioIDEA: Biotech vs COVID-19. Our CEO, Andrew Satz, explains how our technology works, with specific attention to our work on COVID-19. Give it a listen below (transcription beneath video). Transcription: We use nearly a hundred...
EVQLV's very own Andrew Satz (CEO and CO-Founder) was a guest on the M2 Techcast of MITechNews.com with Mike Brennan and Matt Roush. He discussed our work on coronavirus, what is and isn't artificial intelligence, the application of AI, and our mission at EVQLV. Give...
Below is a clip from Andrew Satz's (CEO, EVQLV) speech at the Flatiron School. He explains what we do at EVQLV and how we do it. In short, we use artificial intelligence (AI) to discover and optimize novel biologics. Our algorithm uses an evolutionary approach with...
Note: This post was co-written by Sabyasachi Dash, PhD At the time of writing, more than 2.7 million cases of COVID-19 have been reported globally. Development of a vaccine against the novel coronavirus, SARS-CoV-2, require an investment of 12-18 months. Worse yet,...
Our co-founder and CEO, Andrew Satz, recently gave a talk to data science students at the Flatiron School. He covered our work at EVQLV, our collaboration with ImmunoPrecise, and answered quite a number of questions. One of those...
Our CEO, Andrew Satz, has spent the last 15 years working remotely -- making him a veritable expert on the skill. He was recently a guest on the Gaper podcast where he shared three methods you can quickly implement to help you adjust to remote work. As this has become...
Edward Turner of TMR Blog recently covered our work on COVID-19. He did a nice job summarizing the potential efficacy of our algorithm in an understandable and digestible manner, while including EVQLV's optimism on the project. See below. Andrew Satz is the CEO and...
Brett Averso (CTO, EVQLV) shows and explains the undeniable structural similarities between SARS-CoV-2 and SARS. We hope this video serves to dispel some of the myths you may have encountered during your search for answers surrounding coronavirus. It should be noted...
In the AI vs COVID-19 battle there are three major areas where breakthroughs are needed, coming and have arrived: diagnosis, treatment and epidemiology. In this post, we focus on five companies who are using epidemiology to aid researchers and the general public in...
During my recent conversation with Brett, I posed the question whether we could use SARS antibodies to combat SARS-CoV-2. As Brett explained, the SARS antibodies, when docked against a spike glycoprotein demonstrated poor binding, despite the similarities between the...